Study Title
A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617.
Study Details
Description:
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals (Clarity Clinical)clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
Government Study Link:
NCT05633160 - Click here to see study onClinicalTrials.gov
- • Eastern Cooperative Oncology Group performance status of 0 to 2
- •≥1 Metastatic lesion that is present at screening
- • Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L)
- • Have progressive metastatic castration-resistant prostate cancer (mCRPC)
- • Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa)
- • Spinal metastasis with symptomatic cord compression, or clinical or radiologic findings
- • Prior history of leukemia or Myelodysplastic Syndrome
- • Histologic diagnosis of small cell prostate cancer
- • Symptomatic Brain metastasis
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States